These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30543839)

  • 21. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
    Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
    Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC).
    Kim Y; Vagia E; Viveiros P; Kang CY; Lee JY; Gim G; Cho S; Choi H; Kim L; Park I; Choi J; Chae YK
    Cancer Immunol Immunother; 2021 Apr; 70(4):961-965. PubMed ID: 33084943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma With Kras Mutation After Osimertinib Resistance: A Case Report.
    Li XX
    Am J Ther; 2021 Jul; 29(2):e269-e271. PubMed ID: 33416243
    [No Abstract]   [Full Text] [Related]  

  • 25. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
    Hsieh MS; Lin MW; Lee YH
    Lung Cancer; 2019 Nov; 137():76-84. PubMed ID: 31561203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
    Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
    Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
    Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
    Riedel R; Michels S; Heydt C; Siemanowski J; Kobe C; Bunck A; Schäfer S; Fischer RN; Scheffler M; Abdulla DSY; Nogová L; Koleczko S; Merkelbach-Bruse S; Büttner R; Wolf J
    Lung Cancer; 2019 Jul; 133():20-22. PubMed ID: 31200822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
    Fallet V; Ruppert AM; Poulot V; Lacave R; Belmont L; Antoine M; Cadranel J; Wislez M; Lavolé A
    J Thorac Oncol; 2012 Jun; 7(6):1061-3. PubMed ID: 22588159
    [No Abstract]   [Full Text] [Related]  

  • 32. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
    Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon.
    El Hussein S; Khader SN
    Diagn Cytopathol; 2019 Aug; 47(8):845-850. PubMed ID: 31017747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review.
    Xu G; Zhou L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 49(4):628-636. PubMed ID: 39019792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
    Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
    J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Tokaca N; Wotherspoon A; Nicholson AG; Fotiadis N; Thompson L; Popat S
    Lung Cancer; 2017 Sep; 111():65-68. PubMed ID: 28838401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
    Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
    Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
    Suda K; Murakami I; Yu H; Kim J; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    J Thorac Oncol; 2017 Jun; 12(6):1015-1020. PubMed ID: 28193529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.